New psoriasis pill shows promise in early safety trial

NCT ID NCT05725057

Completed Symptom relief Sponsor: Artax Biopharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either AX-158 or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to see if the drug is safe and tolerable, with some early checks on whether it improves skin symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AX-158
What this could lead to: If it works, this could point toward a new oral treatment option for mild to moderate psoriasis.
What could go wrong: This is a small, early-phase proof-of-concept study with only 31 participants. It focuses on safety, not yet on effectiveness, so results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS PSORIASIS

Contacts and locations

Locations

Accellacare North London

Northwood, United Kingdom
Accellacare Northamptonshire

Corby, United Kingdom
Accellacare South London

Orpington, United Kingdom
Accellacare Warwickshire

Coventry, United Kingdom
Accellacare Yorkshire

Shipley, United Kingdom
MEU

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.